AOD-9604
AOD9604, Tyr-hGH(177-191), hGH fragment 176-191 analog, "anti-obesity drug 9604," Lipotropin fragment (marketing)
The Ground Truth Score
four plain questions, never one numberReal human trials, but the big one failed
Bottom line
One of the very few gray-market peptides with genuine Phase 2 RCT data and a clean human safety record, but its pivotal weight-loss trial missed its primary endpoint, the drug program was abandoned in 2007, and forum results are underwhelming, so the honest read is "safe, well-studied, and probably doesn't do much."
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Reported community/clinic protocols: ~250-500 mcg (0.25-0.5 mg) subcutaneously once daily, commonly in the morning, sometimes titrated up toward ~1 mg/day; often cycled (e.g., 5 days on / 2 off, run for several weeks to a few months).
Reported, not prescribed. Verify your vial and your math.
First documented human use
Human dosing began in Phase 1/2 trials run by Metabolic Pharmaceuticals (Monash University spin-out, Australia) starting around 2001; the published pooled human safety analysis (Stier et al., Journal of Endocrinology and Metabolism, 2013) covers six randomized, double-blind, placebo-controlled trials conducted 2001-2006 in roughly 900 obese adults. Unlike most peptides in this category, controlled human trials WERE completed, but the pivotal Phase 2b efficacy trial failed its primary endpoint and development was halted in 2007.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.
- A 16-amino-acid fragment of the C-terminus of human growth hormone (residues 176-191 with an added tyrosine), engineered to isolate GH's fat-burning action.
- Marketed for fat loss that supposedly works without raising IGF-1, without affecting blood glucose, and without GH's growth/insulin side effects.
- Backed by a genuinely large human safety dataset (~900 subjects across six RCTs) showing tolerability indistinguishable from placebo.
- More recently repurposed by clinics and vendors for joint/cartilage support (often paired with hyaluronic acid), though that use rests almost entirely on animal data.
- Available only as a gray-market research peptide or compounded product; not approved as a drug anywhere and rejected by the FDA for compounding in December 2024.
The data behind each bullet
What actually backs it
A 12-week Phase 2 study (1 mg oral daily, ~34 active vs ~37 placebo) reported statistically significant modest weight loss plus improved glucose tolerance versus placebo.
Single small human RCT with a positive result, reported in the published human literature. Modest effect size; not independently replicated and contradicted by the larger pivotal trial.
PubMed: AOD9604 human metabolic studies ↗The larger pivotal Phase 2b weight-loss trial (multiple doses, several hundred obese adults) FAILED to beat placebo on its primary endpoint, and the drug-development program was terminated in 2007.
Sponsor (Metabolic Pharmaceuticals / Calzada) reporting and trial-update press coverage; this negative result is the single most important efficacy fact and outweighs the small positive study.
ClinicalTrials.gov: AOD9604 ↗Across ~900 obese adults in six RCTs, AOD-9604 showed a safety/tolerability profile indistinguishable from placebo, with no IGF-1 elevation and no adverse effect on glucose metabolism.
Pooled human safety analysis (Stier et al., 2013). Strong safety signal, but it was a safety paper, not an efficacy paper.
PubMed: AOD9604 safety tolerability humans ↗Lipolytic/anti-lipogenic activity is established in rodent fat tissue and obese-mouse models, including via beta-3 adrenergic pathways.
Multiple animal and in-vitro studies (obese mice, beta-3-AR knockout mice). Robust preclinically but does not raise the human evidence grade.
PubMed: AOD9604 lipolysis mouse beta3 ↗Intra-articular AOD-9604 (with or without hyaluronic acid) improved outcomes in a rabbit osteoarthritis model, the basis for the newer 'joint support' marketing.
Single animal (rabbit) study; no human joint/cartilage trials exist. The popular joint-health positioning is animal-only.
PubMed: AOD9604 osteoarthritis rabbit ↗FDA declined to add AOD-9604 to the 503A bulk drug substances list (PCAC, Dec 4 2024), citing limited long-term safety data, peptide impurities, and immunogenicity risk; it is now effectively off-limits for legal compounding.
FDA / Pharmacy Compounding Advisory Committee meeting materials and regulatory coverage. Regulatory fact, not an efficacy claim.
FDA PCAC Dec 2024 meeting materials ↗Mechanism
How it's assumed to work
Assumed mechanism: AOD-9604 mimics the lipolytic C-terminal region of human growth hormone, stimulating fat breakdown (lipolysis) and inhibiting fat formation (lipogenesis) in adipocytes, proposed to act partly through beta-3 adrenergic signaling (cAMP -> protein kinase A -> hormone-sensitive lipase) rather than the GH receptor, which is why it does not raise IGF-1 or impair glucose in trials. This is well supported in rodent fat tissue; whether it produces clinically meaningful lipolysis in humans is exactly what the failed pivotal trial casts doubt on. Not an approved drug, so the mechanism remains "assumed/theoretical" in terms of real-world fat-loss benefit.
Dosing & handling
What users and clinicians report
Reported community/clinic protocols: ~250-500 mcg (0.25-0.5 mg) subcutaneously once daily, commonly in the morning, sometimes titrated up toward ~1 mg/day; often cycled (e.g., 5 days on / 2 off, run for several weeks to a few months). Trial doses spanned 0.25 mg to tens of mg orally and 25-400 mcg/kg IV. Oral and topical/sublingual versions are also marketed despite poor oral bioavailability. This is reported usage, not a prescription.
Dosing is anecdotal and clinic-driven, not established by an approved label. The injectable subcutaneous microgram protocol favored online differs from the oral/IV routes that dominated the trials, so the popular dose is partly inferred. Verify vial mass and reconstitution volume before any dose math, a 5 mg vial reconstituted with 2 mL gives 2,500 mcg/mL, so a "250 mcg" dose is 0.1 mL. Gray-market product purity is unverified and the FDA has flagged impurity/immunogenicity concerns.
Timing & food
Commonly dosed in the morning, frequently fasted, on the theory that low circulating insulin and an overnight-fasted state favor lipolysis and fat oxidation; some users pair it with fasted morning cardio for the same reason. Because the half-life is short, splitting into morning and pre-cardio doses is also reported. Timing rationale is mechanistic/anecdotal, not trial-validated.
Half-life
Short. Plasma half-life is on the order of minutes after IV dosing (~3 minutes reported in pigs); functional/effective half-life is often cited around 30 minutes. Practically it clears the body quickly, which underpins once- or twice-daily dosing and limits accumulation.
Reconstitution sensitivity
Supplied as lyophilized powder; reconstitute with bacteriostatic (or sterile) water. Store lyophilized vials frozen (~ -20 C) or refrigerated; after reconstitution keep refrigerated at 2-8 C and use within roughly 28 days. Avoid repeated freeze-thaw cycles, heat, and vigorous shaking (swirl gently), and protect from light, peptides degrade with rough handling.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Moderate chatter volume. AOD-9604 is a well-known "name" peptide in fat-loss circles and is widely sold, so it is discussed often. But that volume is dominated by vendor blogs, clinic marketing, and affiliate content rather than detailed independent user logs; genuine, specific first-person result reports are comparatively sparse.
Consistency
Reports skew consistently underwhelming: users commonly describe subtle, slow effects at best, often indistinguishable from their diet and training, and frequently conclude it is the most "skippable" peptide in a stack. Few claim dramatic standalone fat loss. This low-key consensus actually aligns with the trial record (small effect, failed pivotal endpoint), which lends it some credibility even though it is anecdote.
Source credibility
Low-to-moderate. The loudest positive sources are vendors and clinics with a financial interest and are discounted. The more credible independent voices (experienced peptide users) tend to be lukewarm. Because almost everyone runs it inside a diet plus other compounds, even sincere positive reports have poor attribution. Net: the believable signal is faint.
- Common sentiment (anecdote, not proof): most users describe the fat-loss effect as subtle and slow at best, and many say it did little or nothing they could distinguish from their diet and training alone.
- It is frequently called the 'optional' or first-to-cut peptide in a stack, people running it with GLP-1 drugs or GH secretagogues often credit those instead.
- Tolerability reports are genuinely good: users rarely report meaningful side effects, with occasional mild injection-site reactions, mild headache, or transient flushing.
- A subset of users running it fasted with morning cardio report feeling 'a bit leaner' or recovering faster from joint aches, but these are soft, subjective impressions consistent with placebo and concurrent dieting.
Placebo risk, Moderate
Fat loss is objectively measurable (scale, calipers, DEXA), which would normally pull placebo risk down to Low. But it is rated Moderate because the genuine effect size is small, it is almost never isolated from diet/training/other drugs, the subjective "I feel leaner" component is easily suggestion-driven, and, most tellingly, the adequately powered pivotal human trial could not distinguish AOD-9604 from placebo. When the registration trial itself fails to separate from placebo, individual users attributing results to it are at real risk of crediting the wrong thing.
Risk panel
What could go wrong
Adverse events
In the ~900-subject human safety dataset, treatment-related adverse events were mild and indistinguishable from placebo, most commonly mild headache and gastrointestinal symptoms. No serious adverse events were attributed to the drug; the handful of SAEs recorded (mostly skin cancers in an older obese cohort) were judged unrelated to treatment. No treatment-related withdrawals. This is an unusually clean human AE profile for this class.
Theoretical concerns
Designed specifically to avoid GH's downsides: across human trials it did NOT raise IGF-1 and did NOT impair glucose tolerance, which is the central safety claim and appears to hold. The main theoretical concerns flagged by the FDA in 2024 are immunogenicity (antibody formation against a peptide fragment) and impurities from synthesis, concerns that apply especially to unregulated gray-market and compounded product of unknown purity rather than to the pharmaceutical-grade material used in trials.
Contraindications
No formal contraindication labeling exists because it is not an approved drug. Prudent avoidance applies in pregnancy/breastfeeding and in active or recent cancer (it is a GH-derived fragment, even if it does not raise IGF-1, and the trial population's skin-cancer cases warrant caution in those with malignancy history). Athletes subject to drug testing must avoid it entirely, it is WADA-prohibited (S2) and detectable. As of Dec 2024 it cannot be legally obtained through compounding pharmacies.
Honest unknowns
No human data beyond ~24 weeks, so long-term safety is genuinely unknown. Real-world gray-market product purity, dose accuracy, and immunogenicity are unverified. The injectable subcutaneous route favored by the community was not the primary route in the efficacy trials (which heavily used oral and IV), so the popular protocol is partly extrapolated. And the central efficacy question, does it produce meaningful fat loss in humans at all, is effectively answered "not reliably" by the failed pivotal trial.
Confound watch
Almost always run alongside a calorie deficit, increased training, and frequently other compounds (tirzepatide/semaglutide GLP-1 agonists, tesamorelin or CJC-1295/ipamorelin GH secretagogues, MOTS-c, stimulant fat-burners). Any fat loss is extremely hard to attribute to AOD-9604 specifically, especially given the small effect size seen even in the positive trial, and the pivotal trial's failure suggests most attributed results are diet, training, or co-administered drugs.
History
Discovery → first use → status
- 1990sResearchers at Monash University (Australia) map GH's fat-reducing activity to a small C-terminal region (~residues 176-191), spinning out Metabolic Pharmaceuticals to develop a fragment drug.
- ~2000-2001Preclinical metabolic and obese-mouse studies of the synthetic lipolytic fragment (AOD9604) published; first-in-human dosing begins.
- 2001-2006Six randomized, double-blind, placebo-controlled human trials conducted in ~900 obese adults (IV and oral; doses from 0.25 mg up to tens of mg).
- ~2004-2006A 12-week Phase 2 study (1 mg oral) reports significant modest weight loss vs placebo, raising hopes for an oral anti-obesity drug.
- 2007Pivotal Phase 2b trial fails its primary weight-loss endpoint; Metabolic Pharmaceuticals halts the formal drug-development program.
- 2011-2013AOD-9604 self-affirmed as GRAS by its sponsor for use in supplements/foods (a company-determined status, NOT FDA approval); 2013 pooled human safety analysis published.
- ~2010s-2020sRepurposed by clinics/compounders for fat loss and (on animal data) joint health; added to WADA's prohibited list (S2).
- Dec 4, 2024FDA Pharmacy Compounding Advisory Committee recommends AOD-9604 NOT be placed on the 503A bulks list, citing immunogenicity, impurity, and long-term-safety concerns; legal compounding access closes.
Verification
The COA standard, applied
Cross-checked against PubMed (animal/in-vitro studies dominate; the key human paper is the 2013 pooled safety analysis), the published 12-week Phase 2 positive result, sponsor/press reporting of the failed pivotal Phase 2b and 2007 program termination, and FDA PCAC December 2024 materials rejecting it for 503A compounding. Forum/vendor sources were read for sentiment only and discounted. The widely repeated "FDA GRAS status" is a sponsor self-affirmed GRAS determination for supplement use, NOT an FDA drug approval, these are routinely conflated by vendors and that distinction is load-bearing.
The full verification standard →Sources
Where this comes from
- PubMed - AOD9604 (all literature; animal/in-vitro dominant) ↗· Core literature search. Confirms human data is thin (2013 pooled safety paper) while most studies are rodent/in-vitro.
- PubMed - AOD9604 safety and tolerability in humans ↗· Pooled human safety analysis (~900 subjects, six RCTs): no IGF-1 rise, no glucose impairment, AEs ~ placebo.
- PubMed - AOD9604 obesity / weight loss ↗· Human weight-loss study context: small positive 12-week study vs the failed larger pivotal trial.
- ClinicalTrials.gov - AOD9604 ↗· Trial registry; supports the discontinued-program / failed-pivotal-endpoint history (development halted 2007).
- FDA Pharmacy Compounding Advisory Committee, Dec 4 2024 materials ↗· FDA basis for declining AOD-9604 on the 503A bulks list: immunogenicity, impurities, limited long-term safety. Not FDA-approved.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.